Cargando…

Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

AIMS: To evaluate diabetic retinopathy (DR) data from across the SUSTAIN clinical trial programme. MATERIALS AND METHODS: The SUSTAIN clinical trial programme evaluated the efficacy and safety of semaglutide, a glucagon‐like peptide‐1 analogue, for the treatment of type 2 diabetes (T2D). In SUSTAIN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vilsbøll, Tina, Bain, Stephen C., Leiter, Lawrence A., Lingvay, Ildiko, Matthews, David, Simó, Rafael, Helmark, Ida Carøe, Wijayasinghe, Nelun, Larsen, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888154/ https://www.ncbi.nlm.nih.gov/pubmed/29178519 http://dx.doi.org/10.1111/dom.13172

Ejemplares similares

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
por: Rodbard, Helena W, et al.
Publicado: (2018)

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
por: Husain, Mansoor, et al.
Publicado: (2020)

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
por: Leiter, Lawrence A., et al.
Publicado: (2019)

Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1‐5 trials
por: Warren, Mark, et al.
Publicado: (2018)

Semaglutide for the treatment of overweight and obesity: A review
por: Bergmann, Natasha Chidekel, et al.
Publicado: (2022)

Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
por: Mann, Johannes F. E., et al.
Publicado: (2021)

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
por: Husain, Mansoor, et al.
Publicado: (2020)

Standardizing the haemoglobin glycation index
por: Hempe, James M., et al.
Publicado: (2021)

Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study
por: Aroda, Vanita R., et al.
Publicado: (2021)

A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
por: Andersen, Andreas, et al.
Publicado: (2021)

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
por: Lingvay, Ildiko, et al.
Publicado: (2022)

Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes
por: Rodbard, H. W., et al.
Publicado: (2016)

d-Ribose as a Contributor to Glycated Haemoglobin
por: Chen, Xixi, et al.
Publicado: (2017)

An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study
por: Lingvay, Ildiko, et al.
Publicado: (2021)

An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal–Bolus Insulin in Type 2 Diabetes
por: Lingvay, Ildiko, et al.
Publicado: (2022)

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis
por: Lingvay, Ildiko, et al.
Publicado: (2020)

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
por: Pratley, Richard E, et al.
Publicado: (2020)

Labile glycated haemoglobin and carbamylated haemoglobin are still critical points for HbA(1c) measurement
por: Desmons, Aurore, et al.
Publicado: (2017)

The Association Between Mean Glycated Haemoglobin or Glycaemic Variability and the Development of Retinopathy in People with Diabetes: A Retrospective Observational Cohort Study
por: Dhatariya, Ketan, et al.
Publicado: (2021)

Soluble CD163 and glycated haemoglobin were independently associated with the progression of diabetic retinopathy in adult patients with type 1 diabetes
por: Hector, Sven, et al.
Publicado: (2023)

Glycated Haemoglobin Levels and Its Effect on Outcomes in Cardiac Surgery
por: Ansari, Daniyal Matin, et al.
Publicado: (2022)

Greater Combined Reductions of HbA(1c) ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators
por: Dungan, Kathleen M., et al.
Publicado: (2023)

Case report: A comatose patient with pregabalin overdose successfully treated with continuous renal replacement therapy
por: Nielsen, Visti Torbjørn, et al.
Publicado: (2023)

An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg
por: Pratley, Richard E., et al.
Publicado: (2021)

Association of socioeconomic status with glycated haemoglobin level and risk factors for diabetic retinopathy: a cross-sectional study in Sichuan, western China
por: Xu, Xinyin, et al.
Publicado: (2023)

Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)
por: Jódar, Esteban, et al.
Publicado: (2020)

The accuracy of haemoglobin A(2) measurements in the presence and absence of haemoglobin S
por: Myburgh, Jane K., et al.
Publicado: (2023)

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
por: Kushner, Robert F., et al.
Publicado: (2020)

Glycated haemoglobin (HbA(1c)) for postmortem diagnosis of diabetes
por: Lepik, Delia, et al.
Publicado: (2018)

Access to insulin delivery devices and glycated haemoglobin in lower-income countries
por: Klatman, Emma Louise, et al.
Publicado: (2020)

Ferrocene-Labelled Electroactive Aptamer-Based Sensors (Aptasensors) for Glycated Haemoglobin
por: Feng, Xue-Qing, et al.
Publicado: (2021)

Abstract 15: Glycemic and body weight responses to oral semaglutide in the PIONEER trial program
por: Kumar, K B Sharan, et al.
Publicado: (2022)

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
por: Lingvay, Ildiko, et al.
Publicado: (2020)

Comparative analysis of glycated haemoglobin, fasting blood glucose and haematological parameters in Type-2 diabetes patients
por: Antwi-Baffour, Samuel, et al.
Publicado: (2023)

Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)
por: Davies, Melanie, et al.
Publicado: (2021)

Glycated haemoglobin as a predictor for metabolic syndrome in non-diabetic Korean adults
por: Sung, K C, et al.
Publicado: (2007)

Study of the effect of altitude on the measurement of glycated haemoglobin using point-of-care instruments
por: Veigne, Sandra W, et al.
Publicado: (2015)

Impact on glycated haemoglobin of a biological response‐based measure of medication adherence
por: Nichols, G. A., et al.
Publicado: (2015)

Glycated Haemoglobin Is Associated With Poorer Cognitive Performance in Patients With Recent-Onset Psychosis
por: Montalvo, Itziar, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rt5kbac7ed96dhd0lt0l0es3gr